FDA
-
-
-
-
-
-
-
MannKind Announces $50 Million Private Placement
-
-
-
-
-
-
-
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
-
-
-
-
-
-
-
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
-
-
-
-
-
-
-
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
-
-
-
-
-
-
-
MannKind gets FDA approval for FUROSCIX in pediatric patients
-
-
-
-
-
-
-
MannKind (MNKD) PT Raised to $11 at H.C. Wainwright
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
329,074 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

